Eli Lilly’s Retatrutide Shows 28% Weight Loss as AUD Market Grows 12.1%
LLY•Eli Lilly’s retatrutide achieved up to 28% weight loss at 80 weeks, reinforcing its lead over Novo’s CagriSema. The alcohol use disorder market is forecast to expand at a 12.1% CAGR through 2036, with Lilly’s AD04 expected to seize the largest market share by 2036.
1. Retatrutide Trial Results
Eli Lilly’s retatrutide showed patients lost as much as 28% of body weight after 80 weeks, outperforming Novo Nordisk’s CagriSema which demonstrated lower average weight reduction. These results strengthen Lilly’s position in the obesity treatment market and highlight its next-generation GLP-1 therapy.
2. Alcohol Use Disorder Market Outlook
The global AUD treatment market is projected to grow at a 12.1% CAGR from 2026 to 2036, driven by novel mechanisms including 5-HT3 pathway and NOP receptor targets. Lilly’s AD04 is forecast to capture the largest share by 2036, potentially supplanting current leader VIVITROL and expanding the company’s psychiatric portfolio.
